Replies to post #173 on Savient Pharmaceuticals Inc (fka SVNTQ)

[papaul]

Three reports today are not helping us.

JMP Securities lowered its stock-investment rating on Savient Pharmaceuticals Inc. (SVNT, $2.86, -$0.12, -4.03%) to market underperform from market perform, citing limited growth potential for the specialty biopharmaceutical company's Krystexxa gout treatment drug.